Name of the Issue:Suraksha Diagnostic Limited

1 Type of Issue (IPO / FPO)

IPO

2 Issue Size (Rs. Cr)

846.25

3 Grade of issue along with name of the rating agency

| Name | Not Applicable |
|-------|----------------|
| Grade | Not Applicable |

4 Subscription Level (Number of times)

1.26 times*

Source: Post Issue Monitoring Report

*The above figure is after technical rejections and excluding Anchor portion

5 QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges

| Particulars | % |
|---|---------------|
| (i) On Allotment (1) | 32.32% |
| (ii)at the end of the 1st Quarter immediately after the listing | 35.83% |
| of the issue (December 31, 2024) | 33.63% |
| (iii) at the end of 1st FY (March 31, 2025) | Not available |
| (iv) at the end of 2nd FY (March 31, 2026) | Not available |
| (v) at the end of 3rd FY (March 31, 2027) | Not available |

⁽¹⁾ Shareholding Pattern, as submitted to the Stock Exchange

6 Financials of the issuer

(Consolidated Rs. in Cr)

| Parameters | 31-03-2025* | 31-03-2026 * | 31-03-2027* |
|---|-------------|--------------|-------------|
| Net Sales/ Income from operations | NA | NA | NA |
| Net Profit for the period | NA | NA | NA |
| Paid-up equity share capital | NA | NA | NA |
| Reserves excluding revaluation reserves | NA | NA | NA |

^{*} Note: Financials for the years have not been disclosed

7 Trading Status in the scrip of the issuer

Company's Equity Shares are listed on BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE")

| Particulars | Status |
|---|-------------------|
| (i) at the end of 1st FY (March 31, 2025) | Frequently traded |
| (ii) at the end of 2nd FY (March 31, 2026) (1) | NA |
| (iii) at the end of 3rd FY (March 31, 2027) (1) | NA |

⁽¹⁾ Trading status has not been disclosed since the the relevant financial years have not been completed

⁽²⁾ QIB holding not disclosed as reporting for the relevant period/ financial years have not been completed

8 Change in Directors of issuer from the disclosures in the offer document

| Particulars | Name of the Director | Appointed / Resigned |
|------------------------------------|----------------------|-------------------------|
| During year ended March 31, 2025 | - | - |
| During year ended March 31, 2026 * | NA | NA |
| During year ended March 31, 2027 * | NA | NA |

^{*} Changes in Directors not disclosed as the relevant fiscal year has not been completed.

9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document

(ii) Actual implementation

Not Available

(iii) Reasons for delay in implementation, if any

Not Available

10 Status of utilization of issue proceeds

(i) as disclosed in the offer document Not Applicable

(iii) Reasons for deviation, if any:

11 Comments of monitoring agency, if applicable

(i) Comments on use of funds Not Applicable

(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document
(iii) Any other reservations expressed by the monitoring agency about the end use of funds

Not Applicable

12 Pricing Data

| Designated Stock Exchange | BSE |
|---------------------------|-------------------|
| Issue Price (Rs.): | 441.00 |
| Listing Date | December 06, 2024 |

| Price parameters | At close of listing day December 6, 2024 At close of 30th calendar day from listing day the control of the calendar day from listing day the control of the calendar day from listing day the calendar day from listing day the control of the calendar day from listing day the cale | As at th | e end of March 31, | 2025 | | |
|---|--|---------------|--------------------|-------------------------|------------------------|----------|
| | | listing day * | Closing price | High (during the FY) | Low (during the FY) | |
| Market Price on Designated Stock Exchange | 417.95 | 377.85 | 277.4 | 257.8 | 449.0 | 233,15 |
| BSE Sensex | 81,510.05 | 79,223.1 | 75,901.4 | 77,414.9 | 85,978.3 | 70,234.4 |
| Sectoral Index | Not applicable | | | | | |

^{*} Where the 30th day / 90th day/ March 31 of a particular year falls on a holiday, the immediately following trading day has been considered

| Price parameters | As at the end of March 31, 2026(1) | | | As at the end of March 31, 2027(1) | | |
|---|------------------------------------|-------------------------|------------------------|------------------------------------|-------------------------|------------------------|
| | Closing price | High (during the FY) | Low (during the FY) | Closing price | High (during the FY) | Low (during the FY) |
| Market Price on Designated Stock Exchange | NA | NA | NA | NA | NA | NA |
| BSE Sensex | NA | NA | NA | NA | NA | NA |
| Sectoral Index | Not Available | | | | | |

Note:

13 Basis for Issue Price and Comparison with Peer Group & Industry Average

| Accounting ratio | Name of Company: (Issuer) | As disclosed in the offer document** | | At the end of 2nd FY March 31, 2025 | At the end of 3rd FY March 31, 2026 |
|------------------|---------------------------|--------------------------------------|---------------|--|---|
| | Issuer (Consolidated) | 4.43 | Not Available | Not Available | Not Available |
| | Peer Group | | | | |
| EPS - Basic | Dr Lal PathLabs | 43.05 | Not Available | Not Available | Not Available |
| (₹ per share) | Metropolis Healthcare | 24.95 | Not Available | Not Available | Not Available |
| (¢ þei Silaie) | Thyrocare | 13.42 | Not Available | Not Available | Not Available |
| | Vijaya Diagnostic | 11.62 | Not Available | Not Available | Not Available |
| | Industry Average | 23.26 | Not Available | Not Available | Not Available |

⁽¹⁾ Price information not disclosed as reporting for the fiscal year has not been completed

| | Issuer (Consolidated) | 33.66 | Not Available | Not Available | Not Available |
|--|-----------------------|--------|---------------|---------------|---------------|
| | Peer Group | | | | |
| | Dr Lal PathLabs | 221.53 | Not Available | Not Available | Not Available |
| NAV per share based on balance sheet (Rs.) | Metropolis Healthcare | 213.98 | Not Available | Not Available | Not Available |
| | Thyrocare | 99.48 | Not Available | Not Available | Not Available |
| | Vijaya Diagnostic | 64.21 | Not Available | Not Available | Not Available |
| | Industry Average | 149.80 | Not Available | Not Available | Not Available |
| | Issuer (Consolidated) | NA | Not Available | Not Available | Not Available |
| | Peer Group | | | | |
| | Dr Lal PathLabs | 77.08 | Not Available | Not Available | Not Available |
| P/E | Metropolis Healthcare | 89.61 | Not Available | Not Available | Not Available |
| | Thyrocare | 65.52 | Not Available | Not Available | Not Available |
| | Vijaya Diagnostic | 86.40 | Not Available | Not Available | Not Available |
| | Industry Average | 79.65 | Not Available | Not Available | Not Available |
| | Issuer (Consolidated) | 14.09% | Not Available | Not Available | Not Available |
| | Peer Group | | | | |
| RONW | Dr Lal PathLabs | 20.35% | Not Available | Not Available | Not Available |
| (%) | Metropolis Healthcare | 12.26% | Not Available | Not Available | Not Available |
| | Thyrocare | 13.34% | Not Available | Not Available | Not Available |
| | Vijaya Diagnostic | 19.77% | Not Available | Not Available | Not Available |
| | Industry Average | 16.43% | Not Available | Not Available | Not Available |

Notes:

- ** Based on Consolidated Restated Consolidated Financial Information as on and for the respective period
- * Source: Audited IND AS financials submitted to stock exchanges for the respective period

14 Any other material information

Announcement

For updates and further information on the material information please visit stock exchanges website www.bseindia.com and www.nseindia.com

Disclaimer

This document is uploaded by SBI Capital Markets Limited ("SBICAP") on its website pursuant to the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012, without having regard to specific objectives, suitability, financial situations and needs of any particular person and does not constitute any recommendation, and should not be construed as an offer to sell or the solicitation of an offer to buy, purchase or subscribe to any securities mentioned therein, and neither this document nor anything contained herein shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. This document does not solicit any action based on the material contained herein. Nothing in these materials is intended by SBICAP to be construed as legal, accounting or tax advice. Past performance is not a guide for future performance. Neither SBICAP and its affiliates, nor its' directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of this document.

The information contained in this document is based on the Red Herring Prospectus and amendments thereto, if any, and/or the Final Prospectus, as amended, if any, as applicable, of the Issuer ("Offer Documents") and the information as provided by the Issuer to SBICAP and available with or provided by the Stock Exchanges / Regulators / Monitoring Agencies from time to time. SBICAP reserves the right to make amendments to this document as and when it deems necessary and also to make additions or deletions to the information contained herein from time to time.

In this context, the 'Issuer" would mean an issuer who has come out with the public issue of its securities as indicated in this document for the respective issues, whose information is being accessed by any person, in this document. The Directors of the Issuer have confirmed in the relevant Offer Documents that the information made available therein is true, fair, correct and adequate. SBICAP has made efforts to ensure that the information is gathered from authentic sources, however, no representation or warranty, expressed or implied, is made or given by or on behalf of SBICAP or its affiliates, nor any person who controls it or any director, officer, employee, advisor or agent of it, or affiliate of any such person or such persons as to the accuracy, authenticity, correctness, completeness or fairness of the information contained in this document and SBICAP or its affiliates or such persons do not accept any responsibility or liability or liability for any such information and therefore, any liability or responsibility is expressly disclaimed. This document has not been approved and will or may not be reviewed or approved by any statutory or regulatory authority in India or by any Stock Exchange in India. This document may not be all inclusive and may not contain all of the information that the

Since neither this document nor any copy of it may be taken or transmitted or distributed or re-distributed into certain jurisdictions, directly or indirectly, which may be restricted by law, persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Neither SBICAP, nor any of its affiliates nor their respective directors, officers and employees will be liable or have any responsibility of any kind for any loss or damage that you may incur in the event of any failure or disruption of this website, or resulting from the act or omission of any party involved in producing or hosting this website or the data contained therein available to you, or from any other cause relating to your access to, inability to access or use of the website or these materials.

This document is issued by SBI Capital Markets Limited without any liability / undertaking / commitment on the part of itself or State Bank of India or any other entity in the State Bank Group, except where it is explicitly stated. Further, in case of any commitment on behalf of State Bank of India or any other entity in the State Bank Group, such commitment is valid only when separately confirmed by that entity.